KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Cash & Equivalents (2016 - 2025)

Exact Sciences (EXAS) has disclosed Cash & Equivalents for 16 consecutive years, with $956.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 59.1% to $956.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $956.0 million through Dec 2025, up 59.1% year-over-year, with the annual reading at $956.0 million for FY2025, 59.1% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $956.0 million at Exact Sciences, up from $789.0 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $1.1 billion in Q1 2021, with the low at $6.1 million in Q1 2025.
  • Average Cash & Equivalents over 5 years is $449.7 million, with a median of $392.5 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents surged 183.18% in 2023, then plummeted 98.24% in 2025.
  • Over 5 years, Cash & Equivalents stood at $315.5 million in 2021, then decreased by 23.13% to $242.5 million in 2022, then surged by 149.65% to $605.4 million in 2023, then decreased by 0.74% to $600.9 million in 2024, then skyrocketed by 59.1% to $956.0 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $956.0 million, $789.0 million, and $11.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.